Eventi SITeCS

Dyslipidaemias: present and future approaches to pharmacological intervention

Sorrento (Na), 9-10, November 2019
[continua a leggere]

Rare Disorders of Lipid Metabolism: from Phenotype to Precision Medicine - III Giornata della Ricerca del Centro E. Grossi Paoletti

Milano, 14 Giugno 2019

[continua a leggere]

ECM FAD

Ipercolesterolemia Familiare Omozigote: approcci diagnostici e terapeutici

[continua a leggere]

Il ruolo del controllo della colesterolemia nella prevenzione primaria e secondaria delle malattie cardiovascolari

[continua a leggere]

Linee Guida Consensus

Area Soci

Newsletter

Per essere informati sulle novità di SITeCS iscrivetevi alla nostra newsletter inserendo il vostro indirizzo di posta elettronica

Diateca

Bookmark and Share

International Workshop - Dyslipidaemias: present and future approaches to pharmacological intervention
Sorrento (Italy), November 9-10, 2019

 

 

 

 

 

Programme

 

 

November 9, 2019




INTRODUCTION
Introduction to the meeting • A.L. Catapano
EAS activities and initiatives • L. Tokgözoglu


PREVENTION: WHEN SHOULD WE START?

Early intervention for future benefit • Matteo Pirro


NON PHARMACOLOGICAL THERAPEUTIC APPROACHES

Lifestyle interventions • Carlos Escobar
Role of nutraceuticals • Maciej Banach
Updates of the clinical evidences • Arrigo G. Cicero


LIPOPROTEINS AND ATHEROSCLEROSIS

What does low HDL‐C mean? • Laura Calabresi
ApoB a common denominator? • Brian Ference
TG lowering benefit: Clinical evidence • Alberto Zambon


DYSLIPIDEMIA MANAGEMENT: THE NEW 2019 EAS/ESC GUIDELINES

The EAS/ESC 2019 Dyslipidemia Guidelines • Alberico L. Catapano
Take home messages from EAS/ESC 2019 Dyslipidemia Guidelines • Lale Tokgözoğlu


CURRENT AND FUTURE THERAPEUTIC APPROACHES

Statins • Lale Tokgözoğlu
Ezetimibe and combination therapy • Luis Masana
PCSK9 inhibitors • Michel Farnier
Novel therapeutic approaches • Alberico L. Catapano

 

November 10, 2019


 

PRESENTATION AND DISCUSSION OF CLINICAL CASES
Low Risk (<1% and LDL >140 mg/dL) • Matteo Pirro, Maciej Banach
High risk patient, with FH, in primary prevention • Lale Tokgözoğlu, Michel Farnier
Initial state of Diabetes, medium‐high risk, high TG • Lluis Masana
High risk patient, with CKD, in primary prevention • Arrigo G. Cicero
High risk patient, with CKD, in primary prevention • Laura Calabresi
High risk patient, patient, Acute Coronary Syndrome • Carlos Escobar

 

 

 



The programme was made possible thanks to an unrestricted educational grant from